Castle Biosciences, announced that the Company has received its Clinical Laboratory Permit from the New York State Department of Health for its laboratory in Pittsburgh. “Castle is committed to serving patients through high-quality molecular tests that inform important care decisions in the management of conditions with high clinical need,” said Kristen Oelschlager, chief operating officer of Castle Biosciences. “Successful completion of the rigorous New York State licensure process for our Pittsburgh laboratory reflects this commitment and expands our ability to positively impact patient care.” Castle operates clinical laboratories in Pittsburgh and Phoenix. With the recent successful inspection in Pittsburgh, both laboratories are now permitted to provide test services to patients and physicians in the state of New York; Castle’s Phoenix laboratory received its permit in early 2018. Both laboratories are also College of American Pathologists accredited and Clinical Laboratory Improvement Amendments certified, reflecting Castle’s commitment to high-quality standards and operational excellence. Earlier this year, Castle doubled the size of its Pittsburgh operations through a move to a new state-of the art laboratory in the city’s historic North Side. The 20,000 square-foot laboratory provides additional capacity that should allow Castle to continue to scale its operations and provide space for future growth. The new laboratory in Pittsburgh brings Castle’s total laboratory operations space to more than 52,000 square feet combined.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CSTL:
- Castle Biosciences management to meet with KeyBanc
- Castle Biosciences announces new TissueCypher study data published
- Castle Biosciences price target raised to $30 from $25 at Baird
- Castle Biosciences raises FY23 revenue view to $180M, consensus $174.47M
- Castle Biosciences reports Q2 EPS (70c), consensus (91c)